Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CSL–NICD interaction is a central event in the canonical Notch signaling pathway, regulating gene expression critical for cell fate decisions. In the absence of NICD, CSL represses transcription. Upon Notch activation, NICD binds to CSL, displacing corepressors and recruiting coactivators (Mam/MAML) to activate transcription. This switch from repression to activation depends on whether corepressors or coactivators are bound to DNA-associated CSL. Recent studies indicate that released nuclear NICDs can transport or stabilize nuclear localization of free cytoplasmic pools of CLS/CSL proteins. The dynamic exchange between repressive/corepressor-bound versus activating/NICID-bound states underlies rapid responsiveness at target loci during developmental patterning or disease processes such as cancer progression or cardiac development/disorders.
Modulation of CSL-NICD interaction to alter transcription of Notch target genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CSL–NICD protein-protein interaction (CSL–NICD).